close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Nanobiotix S.A.

< Previous 1 2 3 4 Next >
News headline image
NANOBIOTIX to Present at the Jefferies Global Healthcare Conference
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
News headline image
NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
News headline image
Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
News headline image
NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
News headline image
NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
News headline image
NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
News headline image
NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
News headline image
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
News headline image
Nanobiotix to Present at Upcoming Investor Conferences in March
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
News headline image
Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
News headline image
Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
News headline image
Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
News headline image
Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
News headline image
NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
News headline image
NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
News headline image
NANOBIOTIX Announces Closing of Global Offering
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
News headline image
NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
News headline image
NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
News headline image
NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
News headline image
NANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation Oncology
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
News headline image
Nanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival of 16.9 Months and Median Overall Survival of 23.1
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
News headline image
NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
News headline image
NANOBIOTIX Provides Business Update and Financial Results for the First Half of 2023
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today